from BioVersys AG
BioVersys Appoints Anca Cighi as Head of Investor Relations and Communications
BioVersys AG / Key word(s): Personnel
BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today the appointment of Anca Cighi as Head of Investor Relations and Communications. Hernan Levett, Chief Financial Officer of BioVersys, said: “BioVersys has successfully advanced its rich pipeline since becoming a listed company. Clear, consistent and timely communication with investors and other stakeholders remains important and integral to the way we conduct our business responsibly in the highly regulated healthcare business. Anca joins us with relevant experience across both investor relations and corporate communications, and we are pleased to welcome her to BioVersys.” Anca Cighi brings 15 years of experience in corporate communications and capital markets advisory. She has held senior in-house and advisory roles supporting listed companies and has extensive experience in stakeholder engagement across international markets. Most recently, she served as Head of Investor Relations & Corporate Affairs at Aramex. Prior to that, she was Senior Director, Strategic Communications, at FTI Consulting and was based in Dubai. Anca Cighi, Head of Investor Relations and Communications of BioVersys, said: “BioVersys is addressing one of the most urgent challenges in global health. The company is now in Phase 3 clinical development with its lead asset BV100 and has a rich pipeline of clinical and pre-clinical assets in parallel. Long-term and new partnerships with GSK and Shionogi testify to the significance, quality and credibility of the company’s programs. I am honoured to join BioVersys at this important stage in its development. I look forward to supporting the team in communicating our strategy, progress and key milestones and maintaining a close relationship with our shareholders.”
About BioVersys BioVersys AG is a multi-asset, clinical stage biopharmaceutical company focused on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria. Derived from the company’s two internal technology platforms (TRIC and Ansamycin Chemistry), candidates are designed and developed to overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria towards the identification of new treatment options in the antimicrobial and microbiome fields. This enables BioVersys to address the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. The company’s most advanced research and development programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 3), and tuberculosis (alpibectir, Phase 2, in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, France). BioVersys is located in the biotech hub of Basel, Switzerland. BioVersys contact
Disclaimer This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning BioVersys and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioVersys to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioVersys is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
|
2302716 02.04.2026 CET/CEST